Association between polymorphisms of APE1 and OGG1 and risk of colorectal cancer in Taiwan

Table 4 Odds ratio and 95%CI of two APE1 single nucleotide polymorphisms for colorectal cancer stratified by sex, age at diagnosis, and tumor site and stage

	APE1 Asp148Glu				APE1 T-656G
	Asp/Asp		Asp/Glu + Glu/Glu		T/T		T/G + G/G
	No.1	OR (95%CI)2	No.1	OR (95%CI)2	No.1	OR (95%CI)2	No.1	OR (95%CI)2
Gender
Male	137/122	1.00 (ref)	264/283	0.83 (0.62-1.12)	128/111	1.00 (ref)	277/296	0.81 (0.60-1.10)
Female	99/127	1.00 (ref)	215/195	1.41 (1.02-1.96)a	89/100	1.00 (ref)	227/224	1.14 (0.81-1.60)
Age at diagnosis (yr)
≤ 60	105/110	1.00 (ref)	213/205	1.09 (0.78-1.51)	108/99	1.00 (ref)	215/219	0.90 (0.65-1.26)
> 60	131/139	1.00 (ref)	266/273	1.03 (0.77-1.38)	109/112	1.00 (ref)	289/301	0.99 (0.73-1.35)
Tumor site
Colon	114/249	1.00 (ref)	231/478	1.06 (0.81-1.40)	105/211	1.00 (ref)	244/520	0.94 (0.71-1.25)
Rectum	122/249	1.00 (ref)	248/478	1.05 (0.81-1.38)	112/211	1.00 (ref)	260/520	0.95 (0.72-1.24)
Stage
0, I, II	106/249	1.00 (ref)	226/478	1.11 (0.84-1.47)	107/211	1.00 (ref)	226/520	0.85 (0.64-1.12)
III, IV	130/249	1.00 (ref)	253/478	1.02 (0.79-1.33)	110/211	1.00 (ref)	278/520	1.03 (0.79-1.36)

¹Number of cases/number of controls;

²Adjustment for age and sex (except in gender stratification, where only sex was adjusted for). The

^aP < 0.05 is the comparison between CRC cases and controls among female in calculating OR for Asp/Glu + Glu/Glu genotype vs Asp/Asp genotype.